Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial

作者：Chunjuan Wang, Hongqiu Gu, Xiaochuan Huo, Baoshi Yuan, S. Li, Jie Xu, Yue Jiang, Jing Jing, Xiaoxi Yao, Zhiliang Li, Faqing Long, Zhengfei Ma, Xianbo Zhuang, Lihua Xu, Yu Jin, Wenguo Huang, Yongqiang Zhang, Jun Wen, A X Wang, Yuesong Pan, Wanxing Ye, Weiran Yu, Aichun Cheng, Meng Wang, Qiang Dong, Anding Xu, Ning Wang, Ying Yang, Xia Meng, Liping Liu, Xinyu Zhao, Hao Li, Zhongrong Miao, Zixiao Li, Yongjun Wang · 发表于：BMJ · 年份：2026 · DOI：10.1136/bmj-2025-086850 · 被引用次数：16 · 研究领域：Acute Ischemic Stroke Management、Neuroinflammation and Neurodegeneration Mechanisms、Intracerebral and Subarachnoid Hemorrhage Research

OBJECTIVE: To assess the efficacy and safety of edaravone dexborneol, a multitarget brain cytoprotectant composed of antioxidant and anti-inflammatory ingredients, in improving functional outcomes among patients with acute ischaemic stroke undergoing endovascular thrombectomy. DESIGN: Multicentre, double blind, randomised, placebo controlled trial. SETTING: 106 hospitals in China between March 2022 and May 2023. PARTICIPANTS: 1362 patients with clinically diagnosed acute ischaemic stroke within 24 hours of symptom onset, aged 18-80 years, with a National Institutes of Health Stroke Scale (NIHSS) score of 6-25 and an Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of 6-10, confirmed large vessel occlusion in the anterior circulation, and planned endovascular thrombectomy. INTERVENTIONS: Patients were randomly allocated in a 1:1 ratio to receive edaravone dexborneol 37.5 mg (edaravone, 30 mg; (+)-dexborneol, 7.5 mg; 690 patients) or placebo (672 patients) before endovascular thrombectomy and continued the regimen twice daily for a consecutive period of 10-14 days. MAIN OUTCOME MEASURES: Functional independence at 90 days, defined as a modified Rankin Scale score (range 0 (no symptoms) to 6 (death)) of 0-2, and serious adverse events. RESULTS: One patient from each group was lost to follow-up at 90 days. Of the 1360 patients included in the intention-to-treat analysis, 379 (55.0%) of 689 patients in the edaravone dexborneol group and 333 (49.6%) of 671 patients ...